Christopher Guttman-McCabe - 06 Aug 2024 Form 4 Insider Report for Anterix Inc. (ATEX)

Signature
s/ Gena L. Ashe, Attorney-in-Fact
Issuer symbol
ATEX
Transactions as of
06 Aug 2024
Net transactions value
$0
Form type
4
Filing time
08 Aug 2024, 17:01:27 UTC
Previous filing
15 Jul 2024
Next filing
19 Nov 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATEX Stock Option (Right to Buy) Award $0 +85,000 $0.000000 85,000 06 Aug 2024 Common Stock 85,000 $33.56 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 27, 2024, the Compensation Committee of the Board of Directors of the Issuer granted the Reporting Person the stock options, at a strike price of $33.56 per share based upon the closing price of the Issuer's common stock on the Nasdaq on such date. In accordance with Nasdaq Listing Rules, the granted stock options were subject to, and were not exercisable until, the Issuer's stockholders approved an authorization of minimum shares of common stock underlying such stock options to exercise the referenced award. On August 6, 2024, stockholders of the Issuer approved Amendment No. 1 to the Issuer's 2023 Stock Plan, which authorized an additional 1,100,000 shares under the Issuer's 2023 Stock Plan and satisfied the award conditions of the Reporting Person's stock option award.
F2 The option shares will vest and become exercisable by the Reporting Person, if he is employed by the Issuer, on March 27, 2027, unless exercisable sooner in accordance with the terms of the award agreement or any other applicable agreement, arrangement or policy of the Issuer.